---
title: "Aarti Drugs Ltd (AARTIDRUGS) — Share Price, Financials & Analysis"
symbol: "AARTIDRUGS"
company: "Aarti Drugs Ltd"
canonical: "https://tapetide.com/stocks/AARTIDRUGS"
isin: "INE767A01016"
nse_symbol: "AARTIDRUGS"
bse_code: "524348"
sector: "Healthcare"
industry: "Pharmaceuticals"
market_cap_cr: 3906.36
generated_at: "2026-09-13T18:25:42.439Z"
---

# Aarti Drugs Ltd (AARTIDRUGS)

Canonical page: https://tapetide.com/stocks/AARTIDRUGS

## Company

- **NSE Symbol:** AARTIDRUGS
- **BSE Code:** 524348
- **ISIN:** INE767A01016
- **Sector:** Healthcare
- **Industry:** Pharmaceuticals
- **Macro Sector:** Healthcare
- **Stock Type:** EQUITY
- **Listed Since:** 2003-09-19
- **CEO:** Mr. Prakash Moreshwar Patil
- **Employees:** 1284
- **Face Value:** ₹10
- **F&O Eligible:** No
- **Website:** aartidrugs.com

## About

Established in the year 1984 and a part of $1000 million Aarti Group of Industries, Aarti Drugs Ltd. (ADL) is engaged into manufacturing and selling Active Pharmaceutical Ingredients (API's), Pharma Intermediates, Specialty Chemicals as well as Formulations. [1]
It is exporting its API's and Speciality chemicals to over 100 countries across the globe. [2]

## Latest Price

- **Price:** ₹428.5
- **Change:** -8.5 (-1.95%)
- **Open:** ₹437
- **Day High:** ₹444
- **Day Low:** ₹426.15
- **Previous Close:** ₹437
- **Volume:** 173089
- **As Of:** 2026-09-11T09:59:56+00:00

## Key Fundamentals

Observed at 2026-09-11T04:54:16.229395Z.

- **Market Cap:** ₹3906.36 Cr
- **Classification:** Microcap
- **P/E (reported):** 20.9
- **P/E (TTM):** 20.45
- **EPS (TTM):** ₹20.95
- **EPS (reported):** ₹17.06
- **Book Value:** ₹169.7
- **Price to Book:** 2.57
- **Dividend Yield:** 0.46%
- **ROE:** 12.58%
- **ROCE:** 12.92%
- **Debt to Equity:** 0.37
- **Revenue (yearly):** ₹2567.7 Cr
- **Net Income:** ₹194.9 Cr
- **EBITDA:** ₹311.6 Cr
- **52-Week High:** ₹534.55
- **52-Week Low:** ₹318.95
- **RSI (14):** 60.85

## Tapetide Score

- **Score:** 54 / 100
- **Score date:** 2026-09-04
- **Archetype:** Quality at a Reasonable Price
- **What it means:** Financial strength is not being paid for with a demanding multiple. The question worth asking is whether the quality is durable or reflects a good patch — check the consistency of returns over several years rather than the latest quarter.
- **Pillar profile:** Quality: Good · Valuation: Cheap · Momentum: Flat
- **Percentile:** 65.6 (of 4473 scored stocks)
- **Confidence:** 100%
- **Data coverage:** 100%

| Pillar | Score | Weight |
| --- | --- | --- |
| financial health | 40.55 | 9% |
| growth | 39.33 | 9% |
| momentum | 53.29 | 12% |
| ownership | 34.92 | 24% |
| quality | 63.6 | 22% |
| valuation | 75.66 | 24% |

The Tapetide Score is decision-support only, not investment advice.

## Key Insights

### Weaknesses

- Stock is trading at 2.53 times its book value
- Promoter holding has decreased over last quarter: -0.60%
- The company has delivered a poor sales growth of 3.55% over past five years.
- Company has a low return on equity of 13.3% over last 3 years.
- Company might be capitalizing the interest cost
- Dividend payout has been low at 6.72% of profits over last 3 years

## Growth Rates

| Metric | QoQ | 1Y | 3Y | 5Y |
| --- | --- | --- | --- | --- |
| cash flow growth | — | 3.66% | -29.36% | 260.09% |
| ebitda margin growth | 0.31% | -3.88% | -4.11% | -11.01% |
| net income growth | -9.4% | 15.94% | 5% | -7% |
| revenue growth | -2.43% | 6.84% | -2% | 4% |
| roce | -0.08% | -9.33% | -21.41% | 16.77% |
| roe | -9.28% | 2.44% | 12.75% | -36.4% |

## Financial Statements

### Quarterly Results

All figures in ₹ crore unless the row name says otherwise.

| Item | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 642 | 606 | 620 | 555 | 598 | 557 | 677 | 591 | 653 | 602 | 720 | 703 |
| Expenses | 565 | 536 | 534 | 490 | 531 | 495 | 583 | 516 | 569 | 547 | 624 | 605 |
| Operating Profit | 76 | 70 | 86 | 65 | 67 | 62 | 93 | 74 | 84 | 55 | 96 | 98 |
| OPM % | 12 | 12 | 14 | 12 | 11 | 11 | 14 | 13 | 13 | 9 | 13 | 14 |
| Other Income | 1 | 2 | 1 | 1 | 1 | 12 | 2 | 0 | 0 | 1 | 1 | -1 |
| Interest | 8 | 8 | 9 | 9 | 9 | 9 | 9 | 9 | 8 | 9 | 8 | 9 |
| Depreciation | 13 | 13 | 14 | 13 | 14 | 14 | 15 | 15 | 16 | 18 | 18 | 18 |
| Profit before tax | 56 | 52 | 64 | 44 | 46 | 51 | 71 | 51 | 60 | 29 | 70 | 69 |
| Tax % | 30 | 29 | 26 | 24 | 24 | 27 | 12 | -6 | 25 | -40 | 21 | 28 |
| Net Profit | 40 | 37 | 47 | 33 | 35 | 37 | 63 | 54 | 45 | 41 | 55 | 50 |
| EPS in Rs | 4.31 | 3.99 | 5.15 | 3.62 | 3.84 | 4.06 | 6.89 | 5.91 | 4.96 | 4.44 | 6.05 | 5.5 |

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 1244 | 1561 | 1806 | 2155 | 2489 | 2716 | 2529 | 2387 | 2565 | 2678 |
| Expenses | 1042 | 1350 | 1541 | 1714 | 2156 | 2407 | 2208 | 2097 | 2254 | 2344 |
| Operating Profit | 202 | 211 | 266 | 440 | 333 | 309 | 321 | 290 | 312 | 333 |
| OPM % | 16 | 14 | 15 | 20 | 13 | 11 | 13 | 12 | 12 | 12 |
| Other Income | 1 | 6 | 6 | 5 | 11 | 2 | 4 | 16 | 2 | 1 |
| Interest | 38 | 44 | 37 | 26 | 24 | 37 | 38 | 39 | 36 | 34 |
| Depreciation | 40 | 43 | 49 | 50 | 50 | 50 | 51 | 56 | 67 | 71 |
| Profit before tax | 125 | 131 | 185 | 369 | 270 | 224 | 236 | 212 | 211 | 229 |
| Tax % | 34 | 32 | 24 | 24 | 24 | 26 | 27 | 21 | 8 | — |
| Net Profit | 82 | 90 | 141 | 280 | 205 | 166 | 172 | 168 | 195 | 191 |
| EPS in Rs | 8.73 | 9.52 | 15.17 | 30.09 | 22.14 | 17.96 | 18.65 | 18.42 | 21.36 | 20.95 |
| Dividend Payout % | 3 | 3 | 3 | 8 | 5 | 6 | 5 | 5 | 9 | — |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Equity Capital | 24 | 24 | 24 | 23 | 93 | 93 | 93 | 92 | 91 | 91 |
| Reserves | 376 | 432 | 520 | 629 | 820 | 944 | 1100 | 1190 | 1278 | 1458 |
| Borrowings | 480 | 546 | 507 | 389 | 351 | 543 | 609 | 564 | 615 | 577 |
| Other Liabilities | 311 | 388 | 405 | 535 | 502 | 629 | 620 | 587 | 591 | 690 |
| Total Liabilities | 1191 | 1389 | 1455 | 1576 | 1766 | 2208 | 2421 | 2432 | 2575 | 2815 |
| Fixed Assets | 581 | 602 | 625 | 644 | 665 | 690 | 676 | 811 | 866 | 1086 |
| CWIP | 14 | 28 | 33 | 12 | 19 | 77 | 210 | 261 | 330 | 214 |
| Investments | 12 | 11 | 12 | 13 | 17 | 19 | 19 | 20 | 22 | 27 |
| Other Assets | 584 | 748 | 785 | 907 | 1064 | 1422 | 1516 | 1340 | 1356 | 1488 |
| Total Assets | 1191 | 1389 | 1455 | 1576 | 1766 | 2208 | 2421 | 2432 | 2575 | 2815 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash from Operating Activity | 175 | 70 | 143 | 251 | 155 | 70 | 133 | 359 | 245 | 254 |
| Cash from Investing Activity | -107 | -74 | -62 | -33 | -72 | -150 | -164 | -224 | -165 | -173 |
| Cash from Financing Activity | -68 | 4 | -80 | -215 | -81 | 92 | 17 | -136 | -82 | -77 |
| Net Cash Flow | 0 | 0 | 1 | 2 | 2 | 13 | -14 | -1 | -2 | 3 |
| Free Cash Flow | 68 | -5 | 80 | 214 | 78 | -82 | -31 | 133 | 67 | 80 |
| CFO/OP | 103 | 47 | 82 | 110 | 57 | 46 | 62 | 131 | 103 | 80 |

### Ratios

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Debtor Days | 91 | 110 | 107 | 99 | 94 | 110 | 116 | 102 | 115 | 118 |
| Inventory Days | 100 | 132 | 86 | 102 | 117 | 115 | 101 | 107 | 114 | 112 |
| Days Payable | 94 | 123 | 85 | 104 | 93 | 103 | 94 | 94 | 100 | 109 |
| Cash Conversion Cycle | 97 | 119 | 109 | 97 | 118 | 123 | 123 | 115 | 129 | 121 |
| Working Capital Days | 22 | 33 | 44 | 54 | 77 | 63 | 72 | 74 | 76 | 76 |
| ROCE % | 18 | 17 | 17 | 21 | 34 | 21 | 15 | 15 | 13 | 12 |

## Shareholding Pattern

### Quarterly

| Category | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Promoters | 58.56% | 57.47% | 57.13% | 55.67% | 55.64% | 55.38% | 55.48% | 55.22% | 54.72% | 55.03% | 55.03% | 54.43% |
| FIIs | 2.33% | 2.1% | 2.56% | 2.96% | 2.5% | 2.28% | 2.25% | 2.26% | 2.69% | 2.15% | 1.58% | 1.52% |
| DIIs | 5.32% | 5.26% | 5.99% | 7.35% | 7.84% | 8.77% | 9.7% | 9.94% | 9.9% | 10.12% | 10.22% | 10.29% |
| Government | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Public | 24.65% | 25.84% | 25.11% | 24.75% | 24.8% | 24.32% | 23.51% | 23.69% | 23.58% | 23.43% | 23.72% | 24.12% |
| Others | 9.14% | 9.33% | 9.2% | 9.27% | 9.21% | 9.24% | 9.06% | 8.89% | 9.11% | 9.27% | 9.46% | 9.63% |
| No. of Shareholders | 167446 | 170414 | 157547 | 150218 | 190281 | 176006 | 169761 | 160260 | 152252 | 148363 | 144946 | 143476 |

## Technical Indicators

Derived from daily closing prices and recomputed each trading session; values move with the market.

- **Overall Signal:** Strong Buy
- **Buy / Neutral / Sell:** 13 / 6 / 0

### Moving Averages — summary: **Strong Buy**

| Indicator | Value | Signal |
| --- | --- | --- |
| SMA (10) | 424.75 | Buy |
| EMA (10) | 425.65 | Buy |
| SMA (20) | 420.47 | Buy |
| EMA (20) | 422.47 | Buy |
| SMA (50) | 415.16 | Buy |
| EMA (50) | 413.17 | Buy |
| SMA (100) | 396.55 | Buy |
| EMA (100) | 403.27 | Buy |
| SMA (200) | 387.37 | Buy |
| EMA (200) | 401.02 | Buy |

### Oscillators — summary: **Buy**

| Indicator | Value | Signal |
| --- | --- | --- |
| RSI (14) | 54.97 | Neutral |
| MACD (12,26,9) | 4.21 | Buy |
| Stochastic (14,3,3) | 58.15 | Neutral |
| ADX (14) | 28.8 | Buy |
| Williams %R (14) | -45.52 | Neutral |
| ATR (14) | 13.83 | High Volatility |
| ROC (12) | 2.51 | Buy |
| Stoch RSI (14) | 55.08 | Neutral |
| UO (7,14,28) | 37.32 | Neutral |

## Analyst Ratings

| Recommendation | Analysts | Share |
| --- | --- | --- |
| Buy | 0 | 0% |
| Hold | 1 | 100% |
| Sell | 0 | 0% |

Based on 1 analyst ratings, observed at 2026-09-11T04:54:15.931024+00:00.

## Filings & Documents

### Exchange Filings & Announcements

| Date | Document |
| --- | --- |
| 2026-09-03 | [Announcement under Regulation 30 (LODR)-Newspaper Publication](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=091d97c4-146c-4856-ba17-f23cee368fc8.pdf) |
| 2026-09-02 | [Reg. 34 (1) Annual Report.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d0adb17e-9bd8-4175-828e-7a489ad5a63d.pdf) |
| 2026-09-02 | [Notice Of 41St Annual General Meeting Of The Company](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c3c89230-0472-49af-afe6-b8b4767fd2fb.pdf) |
| 2026-09-02 | [Business Responsibility and Sustainability Reporting (BRSR)](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=84028fc5-47bf-4b5e-b229-f2213ba28cda.pdf) |
| 2026-09-01 | [Announcement under Regulation 30 (LODR)-Newspaper Publication](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9c5ddacd-7141-4021-ae06-667900af7227.pdf) |
| 2026-08-27 | [Board Meeting Outcome for Approval Of Aarti Drugs Limited Performance Stock Option Plan 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=73d00c53-2807-44ba-9cb3-fde68a370592.pdf) |
| 2026-08-24 | [Board Meeting Intimation for Aarti Drugs Limited - Performance Stock Option Plan 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=1823d1bc-c21d-4537-a82f-7ff67fcba724.pdf) |
| 2026-08-24 | [Closure of Trading Window](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=2d743e0b-9511-446a-b5d9-8c8fbfead113.pdf) |
| 2026-08-14 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=14c53e19-2403-401c-baec-ce3979b5f154.pdf) |
| 2026-08-10 | [Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 ("Listing Regulations")](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d2082444-12ae-4e80-bbda-a7085bccf96f.pdf) |

### Earnings Call Transcripts

| Date | Document |
| --- | --- |
| 2026-08-07 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=27f2d160-ce58-40e6-9f04-4c192a51f752.pdf) |
| 2026-05-23 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0d1723fb-ae4d-49db-9672-de5fd77bdbde.pdf) |
| 2026-02-10 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=12526510-623f-4c1d-8698-a5cd5f755758.pdf) |
| 2025-11-14 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=1be6f5fc-e6b7-4807-832c-63ac97f90a7d.pdf) |
| 2025-07-25 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=713d4b40-7c37-46a7-8a00-3cbb42308964.pdf) |
| 2025-05-12 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=617079fa-ec10-423d-9928-f7d3d1819bf9.pdf) |
| 2025-02-04 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=43f4aa71-65b7-489e-9d31-e79810448d7f.pdf) |
| 2024-11-02 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6fdf1955-f801-4102-86fd-a76096a0ec66.pdf) |
| 2024-08-05 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9d8f4ed0-30e9-42c7-85e2-fd8c3aa1ef5b.pdf) |
| 2024-05-10 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=be128bae-e8ea-4eb9-9074-e07afaf24f88.pdf) |

### Investor Presentations

| Date | Document |
| --- | --- |
| 2026-08-01 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=2f6a82d1-6bfb-4ec0-9794-f5444d5fd453.pdf) |
| 2026-05-16 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=fb7fc987-6255-40f3-8316-1b663f80ecf2.pdf) |
| 2026-02-03 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=5a8d8db7-2785-4ce0-82c9-154468f69abb.pdf) |
| 2025-11-07 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d2f24fc5-1403-4507-8511-5a45fb18ff06.pdf) |
| 2025-09-24 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8408530c-9a97-4c86-85e6-fe7ffbfdb4e9.pdf) |
| 2025-07-19 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=31508af2-3857-41d0-87c6-11cc757f16df.pdf) |
| 2025-05-06 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0b0903a9-7c4f-4bd6-aa65-ad7f91519bc7.pdf) |
| 2025-01-29 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=66ba3057-031b-4784-ab65-4476425adc62.pdf) |
| 2024-10-24 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4cd31747-68a5-4f62-9b2b-5ef3e68208d1.pdf) |
| 2024-09-20 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=abdd4481-cae9-423f-8863-9ba3db07a974.pdf) |

### Results & Financial Statements

| Date | Document |
| --- | --- |
| 2026-07-31 | [Financial Results For The Quarter Ended June 30 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=25a5eeb2-914f-4b48-9e58-8953c84561f8.pdf) |
| 2026-05-15 | [Financial Results For The Quarter And Year Ended March 31 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=fd6a1724-6e63-4b35-8eca-7cf0411fcda6.pdf) |
| 2026-02-03 | [Financials Results For The Quarter And Nine Months Ended December 31 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=06b881ec-e0b0-44db-a760-96791d3a1c50.pdf) |
| 2025-11-07 | [Financial Results For The Quarter And Half Year Ended September 30 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0706d35f-c912-49aa-a306-222baa4dc32f.pdf) |
| 2025-07-18 | [Financial Results For The Quarter Ended June 30 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8d21b39c-a847-4d03-a99c-732102d5beb2.pdf) |
| 2025-05-06 | [Outcome Of The Board Meeting And Financial Results For The Quarter And Year Ended March 31 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8cbe7063-7486-4b1f-b49a-bef6526dce95.pdf) |
| 2025-01-29 | [Financial Results For The Quarter And Nine Months Ended December 31 2024 And Interim Dividend](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c7fc2977-e25b-4eb8-8841-a3d69eb72274.pdf) |
| 2024-10-24 | [Financial Results For The Quarter And Half Year Ended September 30, 2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=83654e8a-1c51-4d42-9686-09692520120d.pdf) |
| 2024-07-26 | [Financial Results For The Quarter Ended June 30, 2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d742fc3c-a4ca-400b-81b8-2f9d2ea5284f.pdf) |
| 2024-05-03 | [Audited Standalone And Consolidated Financial Results For The Quarter And Year Ended March 31, 2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=114f388a-8088-41a1-8583-04981eed3038.pdf) |

### Other Documents

| Date | Document |
| --- | --- |
| 9 Apr - Newspaper publication regarding special window for re-lodgement of transfer requests of physical shares. | [Announcement under Regulation 30 (LODR)-Newspaper Publication 9 Apr - Newspaper publication regarding special window for re-lodgement of transfer requests of physical shares.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/3046c00f-ba07-46b6-a135-a95cf39ccd21.pdf) |
| 8 May - Board meeting on May 15, 2026 to approve audited Q4 and FY2025-26 financial results. | [Board Meeting Intimation for Audited Financial Results For The Quarter And Year Ended March 31, 2026 8 May - Board meeting on May 15, 2026 to approve audited Q4 and FY2025-26 financial results.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/8323a753-0db9-4b67-9359-81a16d79a2bb.pdf) |
| 7 Mar - Aarti Drugs to invest Rs10,00,00,000 in Pinnacle; 78,125 shares at Rs1,280; allotment by March 20, 2026. | [Announcement under Regulation 30 (LODR)-Acquisition 7 Mar - Aarti Drugs to invest Rs10,00,00,000 in Pinnacle; 78,125 shares at Rs1,280; allotment by March 20, 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/465b3082-49dc-4174-9260-42f178f1e4f2.pdf) |
| 7 Apr - Newspaper Publication of Second 100 days Campaign - "Saksham Niveshak". | [Announcement under Regulation 30 (LODR)-Newspaper Publication 7 Apr - Newspaper Publication of Second 100 days Campaign - "Saksham Niveshak".](https://www.bseindia.com/xml-data/corpfiling/AttachHis/03fb4118-73be-4365-8d03-3edd4252afde.pdf) |
| 6 Feb - Awarded power-sector contract worth approximately Rs.91.96 Crore; will augment order book. | [Intimation Of Award Of New Contract 6 Feb - Awarded power-sector contract worth approximately Rs.91.96 Crore; will augment order book.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/c3e846df-a008-4028-ba10-1b3fe6c0084a.pdf) |
| 6 Apr - Submitted Regulation 74(5) certificate for quarter ended March 31, 2026. | [Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 6 Apr - Submitted Regulation 74(5) certificate for quarter ended March 31, 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/85a6ff92-d595-41f1-81c4-f4f771d1681a.pdf) |
| 6 Apr - Aarti Drugs relaunches Saksham Niveshak campaign from April 1 to July 9, 2026 for unclaimed dividends. | [Announcement under Regulation 30 (LODR)-Press Release / Media Release 6 Apr - Aarti Drugs relaunches Saksham Niveshak campaign from April 1 to July 9, 2026 for unclaimed dividends.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/7fa26def-c3e8-4f10-92f5-255ca1f2e20e.pdf) |
| 4 Mar - Officials to attend Investec investor conference March 11, 2026, Trident BKC Mumbai, 10:00–14:00. | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 4 Mar - Officials to attend Investec investor conference March 11, 2026, Trident BKC Mumbai, 10:00–14:00.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/9c36c9d3-aa63-4726-9bc1-e9bb84c1f5f2.pdf) |
| 24 Mar - ICRA reaffirmed Aarti Drugs' ratings: AA- (Stable) long-term, A1+ short-term for Rs 1,452.80 crore on March 24, 2026. | [Announcement under Regulation 30 (LODR)-Credit Rating 24 Mar - ICRA reaffirmed Aarti Drugs' ratings: AA- (Stable) long-term, A1+ short-term for Rs 1,452.80 crore on March 24, 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/82a80826-76a7-4ef8-8a11-1035bf2e1551.pdf) |
| 21 Feb - Submission of News paper Advertisement- Notice to shareholders- Special Window for relodegement of Transfer request of Physical shares in reference to SEBI Circular dated January … | [Announcement under Regulation 30 (LODR)-Newspaper Publication 21 Feb - Submission of News paper Advertisement- Notice to shareholders- Special Window for relodegement of Transfer request of Physical shares in reference to SEBI Circular dated January …](https://www.bseindia.com/xml-data/corpfiling/AttachHis/71b1d7d7-23f7-4648-b7d3-5e94f556486e.pdf) |

### Earnings Call Documents

| Date | Document |
| --- | --- |
| Sep 2025 | [Concall - Sep 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/8408530c-9a97-4c86-85e6-fe7ffbfdb4e9.pdf) |
| Sep 2024 | [Concall - Sep 2024](https://www.bseindia.com/xml-data/corpfiling/AttachHis/abdd4481-cae9-423f-8863-9ba3db07a974.pdf) |
| Sep 2023 | [Concall - Sep 2023](https://www.bseindia.com/xml-data/corpfiling/AttachHis/56c46cb6-18b8-46e9-a4a4-8cf689c836aa.pdf) |
| Oct 2023 | [Concall - Oct 2023](https://www.bseindia.com/xml-data/corpfiling/AttachHis/91d689bc-6948-4c14-bee3-a0f6bc0affb1.pdf) |
| Oct 2022 | [Concall - Oct 2022](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=059a00fe-b723-43f7-a070-601ab17a75d8.pdf) |
| Oct 2022 | [Concall - Oct 2022](https://www.bseindia.com/xml-data/corpfiling/AttachHis/059a00fe-b723-43f7-a070-601ab17a75d8.pdf) |
| Nov 2025 | [Concall - Nov 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/1be6f5fc-e6b7-4807-832c-63ac97f90a7d.pdf) |
| Nov 2024 | [Concall - Nov 2024](https://www.bseindia.com/xml-data/corpfiling/AttachHis/6fdf1955-f801-4102-86fd-a76096a0ec66.pdf) |
| Nov 2021 | [Concall - Nov 2021](https://www.bseindia.com/xml-data/corpfiling/AttachHis/73d2a789-50e0-4e6d-be3c-e60a66d443b4.pdf) |
| May 2026 | [Concall - May 2026](https://www.bseindia.com/xml-data/corpfiling/AttachHis/0d1723fb-ae4d-49db-9672-de5fd77bdbde.pdf) |

### Annual Reports

| Date | Document |
| --- | --- |
| from bse | [Annual Report 2025 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/8fbfe419-cd84-4ea7-9e7c-9ff3639620bb.pdf) |
| from bse | [Financial Year 2025 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/1a314945-6403-4e49-8a39-78446e8349f1.pdf) |
| from bse | [Annual Report 2024 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/4fa89774-ade3-4890-99b5-4acd99c28407.pdf) |
| from bse | [Financial Year 2024 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/0dafd962-7815-4517-aa50-fd2fb759aa34.pdf) |
| from bse | [Annual Report 2023 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/630ea7e6-109f-47fc-9c70-d756d219924d.pdf) |
| from bse | [Financial Year 2023 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/7cc9aa56-5aba-4e02-8f19-ee1bdba02838.pdf) |
| from bse | [Annual Report 2022 from bse](https://www.bseindia.com/bseplus/AnnualReport/524348/73635524348.pdf) |
| from bse | [Financial Year 2022 from bse](https://www.bseindia.com/bseplus/AnnualReport/523838/76053523838.pdf) |

### Earnings Call Recordings

| Date | Document |
| --- | --- |
| 2023-07-24 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c47b8c67-c16a-4f8f-bf6a-9ed33d3d1fe4.pdf) |
| 2022-07-28 | [Recording Of Conference Call](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=1c270be0-688a-4f88-b2b0-49b23134c9e6.pdf) |
| 2022-05-10 | [Recording Of Conference Call](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=21fff3a1-a063-4bc0-a322-3fdf0af29653.pdf) |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-09-13T18:25:42.439Z.